News articles about Revance Therapeutics (NASDAQ:RVNC) have been trending somewhat positive on Monday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Revance Therapeutics earned a news impact score of 0.07 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.200027200663 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of analysts have recently commented on RVNC shares. ValuEngine downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. Cowen set a $55.00 target price on Revance Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Piper Jaffray Companies upped their price target on Revance Therapeutics from $28.00 to $51.00 and gave the stock an “overweight” rating in a report on Tuesday, December 5th. Mizuho reaffirmed a “buy” rating and issued a $54.00 price target on shares of Revance Therapeutics in a report on Friday, January 5th. Finally, Guggenheim reaffirmed a “neutral” rating and issued a $42.00 price target on shares of Revance Therapeutics in a report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $44.30.
Shares of Revance Therapeutics (NASDAQ RVNC) traded up $0.50 during trading on Monday, hitting $30.20. The company’s stock had a trading volume of 197,016 shares, compared to its average volume of 334,159. Revance Therapeutics has a fifty-two week low of $18.00 and a fifty-two week high of $37.45. The firm has a market capitalization of $1,062.48, a PE ratio of -7.82 and a beta of 1.36.
In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total transaction of $189,544.00. Following the completion of the transaction, the chief executive officer now owns 133,188 shares of the company’s stock, valued at $3,321,708.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 18.86% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Revance Therapeutics (NASDAQ:RVNC) Receiving Somewhat Favorable Press Coverage, Report Shows” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/12/revance-therapeutics-rvnc-getting-somewhat-positive-news-coverage-study-finds.html.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.